November 15, 2021 – PharmaEssentia's Besremi® (ropeginterferon alfa-2b-njft) has been approved to treat polycythemia vera (PV) in adults. It is the only interferon drug FDA approved for this indication. PV is a rare blood cancer that occurs when the bone...

November 15, 2021 – The U.S. FDA has approved a new indication for Ruxience® (rituximab-pvvr), Pfizer's biosimilar for Genentech and Biogen's Rituxan® (rituximab). Ruxience is now indicated for use in combination with methotrexate to treat adults who...

November 15, 2021 – Mvasi® (bevacizumab-awwb) has received a new indication to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. The drug, manufactured by Amgen, is a biosimilar for Genentech's Avastin® (bevacizumab). Under the new...

November 18, 2021 – The U.S. FDA is expanding a black box warning, the most prominent warning that can be required on a drug label, for Bayer's Climara Pro® (estradiol/levonorgestrel) transdermal patch. Climara Pro is used to treat the symptoms of menopause...

November 19, 2021 – The U.S. FDA has approved VoxzogoTM (vosoritide) for injection to increase linear growth in pediatric patients at least five years of age who have achondroplasia and open epiphyses (growth plates). Achondroplasia is a genetic disorder...

Adults who received the Pfizer/BioNTech or Moderna vaccine for primary vaccination can receive a booster dose of either product at least six months after completing primary vaccination.Adults who received the Janssen (Johnson & Johnson) vaccine for primary...